Potassium Bicarbonate
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Potassium Bicarbonate: From Peptic Ulcer Disease to Gastroduodenitis
One-Sentence Summary
Potassium bicarbonate is an alkalinising agent originally used for acid-related upper gastrointestinal conditions (peptic ulcer disease, reflux disease, esophagitis, dyspepsia) and for potassium deficiency. The TxGNN model predicts it may be effective for gastroduodenitis, but there are currently 0 clinical trials and 0 publications directly supporting this indication, so the prediction rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Peptic ulcer disease, potassium deficiency, gastroesophageal reflux disease, esophagitis, dyspepsia (the registration records in Singapore contain no approved indication text) |
| Predicted New Indication | Gastroduodenitis |
| TxGNN Prediction Score | 99.72% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not currently available. Based on known information, potassium bicarbonate is an alkalinising agent that can neutralise gastric acid. In Singapore it is marketed as a component of alginate/antacid suspensions.
Gastroduodenitis is an acid-related inflammation of the stomach and duodenal lining, so acid neutralisation is mechanistically plausible. However, the high TxGNN score most likely reflects the drug's closeness in the knowledge graph to its existing indications (peptic ulcer disease, esophagitis, dyspepsia). It is not evidence of independent efficacy. The new indication is therefore largely an extension of the existing acid-related use rather than a distinct repurposing opportunity.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for gastroduodenitis.
Among the other lower-ranked predictions, the few papers retrieved were indirect: a 1977 acetazolamide study on distinguishing benign from malignant gastric ulcers (PMID 883470), a 2013 systematic review of raft-forming agents for reflux in pregnancy (PMID 24096290), and unrelated device or physiology papers. None evaluates potassium bicarbonate on its own.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN12635P | Gaviscon Advance – Peppermint Flavour Suspension | Suspension | Not specified in registration record |
| SIN16042P | Gascovid Advance Liquid | Suspension | Not specified in registration record |
Safety Considerations
- Contraindications suggested by the knowledge graph (not taken from the package insert): congestive heart failure, anuria, atrioventricular block, hyperkalaemic periodic paralysis, periodic paralysis, hypoaldosteronism, myotonia congenita. Most relate to the risk of potassium accumulation.
- Drug interactions: 59 interactions were recorded. Major-level interactions include:
- ACE inhibitors: fosinopril, benazepril, captopril, enalapril
- Angiotensin receptor blockers: olmesartan, valsartan, azilsartan medoxomil, eprosartan
- Potassium-sparing diuretics and aldosterone antagonists: amiloride, spironolactone, eplerenone
The shared concern is hyperkalaemia.
- Moderate-level interactions include NSAIDs (ketorolac, ibuprofen, diclofenac, oxaprozin, bromfenac, diflunisal, etodolac), aliskiren and drospirenone.
Please refer to the package insert for label-based warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no supporting clinical trials or literature (L5, model prediction only). The high score mainly reflects proximity to existing acid-related indications. The potassium load also creates a hyperkalaemia risk in patients taking renin-angiotensin system drugs or potassium-sparing diuretics, or with renal impairment.
To proceed, the following is needed:
- Package insert warnings and contraindications from HSA (a blocking gap for safety screening)
- Mechanism of action data from DrugBank
- Clinical or observational evidence specific to gastroduodenitis and potassium bicarbonate
- Clarification of whether gastroduodenitis falls within the existing approved acid-related indications, which would make this less a true repurposing case
- A hyperkalaemia risk-management plan for patients on interacting drugs or with renal impairment
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.